Università della Svizzera italiana

Role of ETS1 in the transcriptional network of diffuse large B cell lymphoma of the activated B cell-like type

Priebe, Valdemar ; Sartori, Giulio ; Napoli, Sara ; Chung, Elaine Yee Lin ; Cascione, Luciano ; Kwee, Ivo ; Arribas, Alberto Jesus ; Mensah, Afua Adjeiwaa ; Rinaldi, Andrea ; Ponzoni, Maurilio ; Zucca, Emanuele ; Rossi, Davide ; Efremov, Dimitar ; Lenz, Georg ; Thome, Margot ; Bertoni, Francesco

In: Cancers, 2020, vol. 12, no. 7, p. 17 p

Diffuse large B cell lymphoma (DLBCL) is a heterogenous disease that has been distinguished into at least two major molecular entities, the germinal center-like B cell (GCB) DLBCL and activated-like B cell (ABC) DLBCL, based on transcriptome expression profiling. A recurrent ch11q24.3 gain is observed in roughly a fourth of DLBCL cases resulting in the overexpression of two ETS transcription...

Università della Svizzera italiana

The novel TORC1/2 kinase inhibitor PQR620 has anti-tumor activity in lymphomas as a single agent and in combination with venetoclax

Tarantelli, Chiara ; Gaudio, Eugenio ; Hillmann, Petra ; Spriano, Filippo ; Sartori, Giulio ; Aresu, Luca ; Cascione, Luciano ; Rageot, Denise ; Kwee, Ivo ; Beaufils, Florent ; Zucca, Emanuele ; Stathis, Anastasios ; Wymann, Matthias P. ; Cmiljanovic, Vladimir ; Fabbro, Doriano ; Bertoni, Francesco

In: Cancers, 2019, vol. 11, no. 6, p. 775

The phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signaling cascade is an important therapeutic target for lymphomas. Rapamycin-derivates as allosteric mTOR complex 1 (TORC1) inhibitors have shown moderate preclinical and clinical anti-lymphoma activity. Here, we assessed the anti-tumor activity of PQR620, a novel brain penetrant dual TORC1/2 inhibitor, in 56...